Top Life Sciences Companies To Invest In Right Now

Veeva Systems Inc., a California-based company that makes cloud software solutions for the life sciences industry, has filed an amended Form S-1 with the Securities and Exchange Commission for an initial public offering (IPO) of 13 million Class A shares priced between $12 and $14 a share.

Selling stockholders are offering 3.33 million shares and the rest are being offered by the company. The underwriters have an overallotment option on an additional 1.96 million shares.

The company has two classes of common stock that are priced equally, but Class B shares are entitled to 10 votes each while Class A shares are entitled to one vote per share. After the offering, holders of Class B shares will hold about 98.5% of the voting power of outstanding shares, and the company�� officers, directors and their affiliates will hold about 74% of the voting power in the company.

Veeva plans to use its share of the proceeds, estimated at $138.3 million if the underwriters��options are taken and the shares are priced at the mid-point of the estimated range, for general corporate purposes and working capital. In its filing the company said, “[W]e do not currently have specific planned uses of the proceeds. The amount of proceeds we use for the purposes above, if any, will depend on the level of cash generated from our operations.”

Top Life Sciences Companies To Invest In Right Now: Dejour Energy Inc (DEJ)

Dejour Energy Inc. is engaged in the business of acquiring, exploring and developing energy projects with a focus on oil and gas exploration in Canada and the United States. The Company holds approximately 113,000 net acres of oil and gas leases in the Peace River Arch of northwestern British Columbia and northeastern Alberta, Canada and the Piceance, Paradox and Uinta Basins in the United States Rocky Mountains. The Company has 71.43% working interest in this 3,014 acre (gross) project located south of Roan Creek. The Company also has 71.43% working interest in this 18,000 acre (gross) project located north of the Rangely Field, is prospective for oil in the Lower Mancos (Niobrara), Dakota, Morrison and Phosphoria formations. Advisors' Opinion:

• [By CRWE]

  Vancouver, BC, Dec. 16, 2013 — (CRWE Press Release) — Dejour Energy Inc. (NYSE MKT:DEJ) (TSX:DEJ), an independent oil and natural gas exploration and production company operating in North America’s Piceance Basin and Peace River Arch regions, today announces that it has signed a Letter of Intent to create a strategic joint venture partnership with a private Singapore based energy company (��ECO�� to develop the company�� Colorado oil and gas assets.

  Upon completion of due diligence, legal documentation and requisite approvals expected prior to January 31, 2014, SECO will invest an initial sum of up to $27.5mm in 2014 and 2015 to earn an 85% share in Dejour�� interests in its Colorado properties, primarily Kokopelli, subject to certain interest claw backs available to Dejour. Following this capital investment by SECO, the partners will continue to judiciously develop the reserves on a pro rata basis.

  The terms of the agreement include a capital injection to Dejour of approximately US$ 4.5mm, including cash and assumption of certain liability agreements on outstanding debt and the 100% development funding of an initial $10.5mm in capital expenditures in 2014 with a further $12mm in 2015, targeting Kokopelli, subject to certain provisions. Additionally, SECO will assume 85% of the ongoing overhead of Dejour�� U.S. operations and joint project management during the initial period. SECO will also share responsibility to maintain the other Dejour U.S. leases in good standing on a pro rata ownership basis or return them to Dejour in a timely fashion. Dejour will remain the operator of record.

  ��ECO shares Dejour�� value proposition relating to the company�� U.S. E&P portfolio. This partnership will bring many strategic advantages to Dejour: minimizing capital requirement in the short term, bolstering the company�� balance sheet and long term US cash flow, the provision of flexibility for Dejour to pursue new

Top Life Sciences Companies To Invest In Right Now: United States Natural Gas Fund LP (UNG)

United States Natural Gas Fund, LP (USNG) is a limited partnership. The Company is a commodity pool that issues limited partnership interests (units) traded on the NYSE Arca, Inc. (the NYSE Arca). The investment objective of USNG is for the changes in percentage terms of its units��net asset value (NAV) to reflect the changes in percentage terms of the spot price of natural gas delivered at the Henry Hub, Louisiana as measured by the changes in the Futures Contract on natural gas traded on the New York Mercantile Exchange (NYMEX) that is the near month contract to expire, except when the near month contract is within two weeks of expiration, in which case the futures contract will be the next month contract to expire. The Company�� general partner is United States Commodity Funds LLC (the General Partner) and is responsible for the management of USNG.

USNG invests in futures contracts for natural gas, crude oil, heating oil, gasoline, and other petroleum-based fuels that are traded on the NYMEX, ICE Futures or other United States and foreign exchanges (collectively, Futures Contracts). USNG also invests in other natural gas-related investments, such as cash-settled options on Futures Contracts, forward contracts for natural gas, cleared swap contracts, and over-the-counter transactions that are based on the price of natural gas, oil and other petroleum-based fuels, Futures Contracts and indices based on the foregoing (collectively, Other Natural Gas-Related Investments). USNG invests in Natural Gas Interests to the fullest extent possible. In pursuing this objective, the primary focus of the General Partner is the investment in Futures Contracts and the management of USNG�� investments in short-term obligations of the United States of two years or less (Treasuries), cash and/or cash equivalents for margining purposes and as collateral.

Advisors' Opinion:

• [By Dan Caplinger]

  Still, rising natural gas prices have likely been the major cause for Exelon's recent share-price rise. With gas prices now double what they were at last year's lows and the nat-gas tracking United States Natural Gas ETF (NYSEMKT: UNG  ) up more than 45% in the past year, Exelon's nuclear fleet is finally starting to look a bit more attractive compared to its peers.

Top 10 Promising Stocks To Watch For 2015: M&T Bank Corporation (MTB)

M&T Bank Corporation operates as the holding company for M&T Bank and M&T Bank, National Association that provide commercial and retail banking services to individuals, corporations and other businesses, and institutions. It offers business loans and leases; business credit cards; deposit products, such as demand, savings, and time accounts; and financial services, including cash management, payroll and direct deposit, merchant credit card, and letters of credit. The company also provides residential real estate loans; multifamily commercial real estate loans; commercial real estate loans; one-to-four family residential mortgage loans; investment and trading securities; short-term and long-term borrowed funds; brokered certificates of deposit and interest rate swap agreements related thereto; and branch deposits. In addition, it offers foreign exchange, as well as asset management services. Further, the company provides consumer loans, and commercial loans and leases; cred it life, and accident and health reinsurance; and securities brokerage, investment advisory, and insurance agency services. As of December 31, 2009, it had 738 banking offices in New York State, Pennsylvania, Maryland, Delaware, New Jersey, Virginia, West Virginia, and the District of Columbia; a commercial banking office in Ontario, Canada; and an office in George Town, Cayman Islands. The company was founded in 1969 and is headquartered in Buffalo, New York.

Advisors' Opinion:

• [By Lauren Pollock]

  M&T Bank Corp.(MTB) and Hudson City Bancorp Inc.(HCBK) said they expect additional delays in completing their merger deal, and any action isn’t expected to occur until the latter half of 2014. “While all parties are disappointed that the transaction is delayed further, we are gratified that M&T continues to see the value in the Hudson City franchise,” said Hudson City CEO Ronald E. Hermance Jr.

• [By Jonas Elmerraji]

  The most-hated name on our list today is M&T Bank (MTB), the $16 billion regional banking stock that tips the scales as one of the 20 largest banks in the country (and is one of Warren Buffett's favorite stocks). With a short interest ratio of 27.22, it would take more than five weeks of buying pressure for short sellers to exit their bets at current volume levels. That means that just about any catalyst could trigger a short squeeze right now.

  M&T Bank was one of the well-run regional names that actually fared well in the wake of the 2008 financial crisis. By actually sticking to retail and commercial banking and maintaining better underwriting standards, MTB ended up with a loan book that was high enough quality to make it through the lean years. Like other banking names, MTB sought to grow its business by acquiring smaller banking names -- and that's one of the big black clouds that investors are fixating on right now. Shares are seeing high short interest thanks to a regulatory edits to improve risk management and a pending acquisition of Hudson City Bancorp (HCBK) that's been a debacle.

  All of that negative sentiment has been piling up for the last two years (meanwhile, net margins are consistently above 25% and shares have actually managed to rally more than 62% over that stretch). The sheet amount of event risk surrounding earnings and the Hudson City merger make the prospect of being short here pretty scary. As soon as shorts start covering, expect a chain reaction.

  Read More: 12 Stocks Warren Buffett Loves in 2014

• [By The Part-time Investor]

  The following stocks met the criteria in January of 2008 and were put into the initial portfolio:

  Abbot Labs (ABT)Advanced data processing (ADP)Associated Banc-Corp (ASBC)Bank of America (BAC)BB&T Corp. (BBT)Bemis Company (BMS)Anheuser Busch (BUD)The Chubb Corporation (CB)Clorox (CLX)Comerica Inc. (CMA)Diebold Inc. (DBD)Emerson Electronics (EMR)First Dollar Corp. (FDO)First Third BanCorp. (FITB)Gannett Co, Inc. (GCI)General Electric (GE)Hershey (HSY)Illinois Tools Works (ITW)Johnson and Johnson (JNJ)Leggett and Platt (LEG)Eli Lilly (LLY)La-Z-Boy (LZB)McDonald's (MCD)Marsh and Ilsley (MI)M&T Bancorp (MTB)PepsiCo (PEP)Pfizer (PFE)Procter & Gamble (PG)Pentair Ltd. (PNR)Regions Financial Corp. (RF)Rohm and Haas (ROH)RPM International (RPM)Sherwin Williams (SHW)Sysco Corp. (SYY)UDR Inc. (UDR)

  Historical quotes were taken from Yahoo Finance. $10,000 was put into each position, to the nearest whole share, so a total of $349,262.89 was invested. From 1/15/08 through 5/16/13 all dividends were reinvested back into the stock that paid them. If a dividend cut was announced, that stock was sold on the ex-div date of the new, lower dividend.

Top Life Sciences Companies To Invest In Right Now: The Blackstone Group L.P.(BX)

The Blackstone Group, L.P., together with its subsidiaries, provides alternative asset management and financial advisory services worldwide. The company operates in five segments: Private Equity, Real Estate, Hedge Fund Solutions, Credit Businesses, and Financial Advisory. The Private Equity segment involves in private equity investing through five general private equity funds and one specialized fund focusing on communications-related investments. This segment engages in various transactions comprising leveraged buyout acquisitions of seasoned companies, transactions involving growth equity or start-up businesses in established industries, minority investments, corporate partnerships, distressed debt, structured securities, and industry consolidations. The Real Estate segment manages general opportunistic real estate funds and internationally focused opportunistic real estate funds. This segment also has debt investment funds targeting non-controlling real estate debt-rel ated investment opportunities in the public and private markets, primarily in the United States and Europe. The Hedge Fund Solutions segment manages funds of hedge funds, and Indian-focused and Asian-focused closed-end mutual funds. The Credit Businesses segment manages credit-oriented funds, CLOs, credit-focused separately managed accounts, and publicly registered debt-focused investment companies. The Financial Advisory segment offers financial and strategic advisory, including corporate finance, and mergers and acquisitions advice; restructuring and reorganization advisory; and fund placement services for alternative investment funds. Blackstone Group Management L.L.C. operates as the general partner of the company. The Blackstone Group, L.P. was founded in 1985 and is headquartered in New York, New York.

Advisors' Opinion:

• [By MONEYMORNING.COM]

  The deal, backed by Kanas and Ross, drew in private equity partners Blackstone Group LP (NYSE: BX), Carlyle Group LP (Nasdaq: CG), and Centerbridge Partners LP, a private investment firm.

• [By Shah Gilani]

  Today, in New York, investors will be pitched the first-ever REO-to-rental securitization deal. The $500 million deal bundles foreclosed single-family homes, "real-estate-owned" by Blackstone Group L.P. (NYSE: BX) , into securities that pass-through rental payments to investors.

• [By Maria Armental and Anna Prior]

  Independent refiner PBF Energy Inc.(PBF) announced a secondary offering of 18 million shares by funds affiliated with Blackstone Group LP(BX) and First Reserve Management LP. Shares of PBF Energy fell 4.3% to $30.04 in premarket trading.

Top Life Sciences Companies To Invest In Right Now: MFC Industrial Ltd (MIL)

MFC Industrial Ltd., formerly Terra Nova Royalty Corp., is a global commodity supply chain company that sources and delivers commodities and materials to clients all over the world. The Company is engaged in the financing and risk management aspect of the business. The Company operates in three segments: commodities and resources, which includes its commodities activities and mineral interests; merchant banking, which includes structured solutions, logistics and financial services and investing activities, and other, which encompasses its corporate and other investments and business interests, including its medical supplies and servicing business. In December 2011, the Company acquired Pea Ridge Iron Ore Mine in Missouri, the Unites States of America. In September 2012, its indirect wholly owned subsidiary acquired the remaining interest in Compton Petroleum Corporation. In November, 2012, it acquired 70% interest in Park Ridge, NJ-based ACC Resources Co., L.P. (ACCR) and 60% interest in Mexico City-based Possehl Mexico S.A. de C.V. (Possehl). In April 2013, 0915988 BC Ltd acquired the entire share capital of MFC Industrial Ltd.

Commodities and Resources

The Company�� supply chain business is globally focused and includes its integrated commodities operations and its mineral interests. It conducts such operations primarily through its subsidiaries based in Vienna, Austria and supply various commodities, including minerals and metals, chemicals, plastics and wood products to its customers. Through its global commodity supply chain business, it also provides logistics, supply chain management and other services to producers and consumers of commodities. Its commodities operations include sourcing and supplying commodities. The Company sources its commodities from Asia, Africa, Europe, Australia, the United States and the Middle East. Its commodities sales include the European, Middle Eastern, Asian and North and South American markets.

Merchant Banking

The Company�� merchant banking operations include merchant banking and financial services, specialized banking, third-party financing and other services, investing and its real property. Its activities include making investments through investing its own capital to capture investment opportunities. The Company focuses on meeting the financial needs of small to mid-sized companies and other business enterprises primarily in Europe and Asia. Its merchant banking business generates revenues in the form of corporate and trade finance service fees and interest income. It also realizes gains from time to time on its investments, upon their sale, the execution of an equity or debt .

Other

Its other segment include its corporate and other investments, It includes financing joint ventures through its Shanghai, China-based subsidiary which provides medical services, equipment and supplies.

Advisors' Opinion:

• [By Rich Duprey]

  Global commodity supply chain company�MFC Industrial (NYSE: MIL  ) announced yesterday its third-quarter dividend of $0.06 per share, the same rate it's paid for the past year.

• [By Tim Melvin]

  Just last week I went around the world with a stock screener to see if any cheap and appealing stocks appeared. At the top of my international buy list right now is Canada-based�MFC Industrial (MIL). MIL has also shown up on my screen for “perfect stocks” since it trades below book value, is profitable and pays a dividend.

Top Life Sciences Companies To Invest In Right Now: Profire Energy Inc (PFIE)

Profire Energy, Inc., incorporated on May 5, 2003, is engaged in the business of developing combustion management technologies for the oil and gases industry. The Company manufactures, install and service oilfield combustion management technologies and related products, such as train components and secondary airplates. The Company's primary products are burner management systems. The Company�� Profire 2100 burner management system allows the end-user to manage a variety of combustion vessels. Its Profire 1300 is a flare-ignition system that provides fundamental ignition capabilities for combustor and open-flare vessels, and can relay flame-status. Its Profire 1800 is a mid-range burner management system option that provides fundamental burner management functionality, such as burner re-ignition and temperature management.

The Company also manufactures other technologies and products for sale, including specialized burner management systems intended for use in specific firetube vessels (e.g. incinerators), valve train products, including valves, gauges, and installation products, and miscellaneous componentry, such as solar-power generation kits, add-on cards to expand the functionality of a given system, and a airplate that meters secondary airflow to the burner, allowing for more optimized combustion and reduced emissions.

The Company competes with SureFire, Platinum, ACL and TitanLogix.

Advisors' Opinion:

• [By Peter Graham]

  Small cap green stocks Eco Depot Inc (OTCMKTS: ECDP), Eco Building Products Inc (OTCMKTS: ECOB) and Profire Energy, Inc (OTCBB: PFIE) has been getting some extra attention lately in various investment newsletters thanks to paid promotions or investor relation campaigns. Of course, there is nothing wrong with properly disclosed promotions and investor relations campaigns, but small cap green stocks tend to be extra volatile when compared with other stocks. So how in greenbacks will these three small cap green stocks produce for investors? Here is a quick reality check:

Top Life Sciences Companies To Invest In Right Now: Nucor Corporation(NUE)

Nucor Corporation, together with its subsidiaries, engages in the manufacture and sale of steel and steel products in North America and internationally. It operates through three segments: Steel Mills, Steel Products, and Raw Materials. The Steel Mills segment produces hot and cold-rolled sheet steel; plate steel; structural steel comprising wide-flange beams, beam blanks, and sheet piling; and bar steel, such as blooms, billets, concrete reinforcing bar, merchant bar, and special bar quality products. The Steel Products segment offers steel joists and joist girders, steel deck, fabricated concrete reinforcing steel, cold finished steel, steel fasteners, metal building systems, light gauge steel framing, steel grating and expanded metal, and wire and wire mesh products. The Raw Materials segment produces direct reduced iron (DRI); brokers ferrous and nonferrous metals, pig iron, hot briquetted iron, and DRI; supplies ferro-alloys; and processes ferrous and nonferrous scrap metal products. The company?s operations also include various international trading companies that buy and sell steel and steel products. It sells its hot-rolled steel and cold-rolled steel to steel service centers, fabricators, and manufacturers; steel joists and joist girders, and steel deck to general contractors and fabricators; and cold finished steel and steel fasteners to distributors and manufacturers. The company?s products are used by contractors in constructing highways, bridges, reservoirs, utilities, hospitals, schools, airports, stadiums, and high-rise buildings. Nucor Corporation was founded in 1940 and is based in Charlotte, North Carolina.

Advisors' Opinion:

• [By GURUFOCUS]

  Nucor Corporation (NUE) engages in the manufacture and sale of steel and steel products in North America and internationally. Dec. 4, the company increased its quarterly dividend 0.7% to $0.37 per share. the dividend is payable Feb. 11, 2014, to stockholders of record on Dec. 31, 2013. The yield based on the new payout is 2.8%.

Top Life Sciences Companies To Invest In Right Now: Insys Therapeutics Inc (INSY)

Insys Therapeutics, Inc., incorporated on June 15, 1990, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The Company�� pharmaceuticals portfolio consists of one approved product and a number of product candidates targeting cancer-supportive care and cancer therapy. The Company�� product candidate includes Subsys, Dronabinol SG Capsule, Dronabinol RT Capsule, Dronabinol Oral Solution, Dronabinol Inhalation Device, and Dronabinol IV Solution. The Company is also developing cancer therapeutics, which is LEP-ETU, a formulation of paclitaxel, the active ingredient in the cancer drugs Taxol and Abraxane. On August 19, 2011, the Food & Drug Administration (FDA) approved its Dronabinol SG Capsule product, a generic equivalent to Marinol, for the treatment of chemotherapy induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with acquired immune deficiency syndrome (AIDS).

Subsys

The Company's Subsys is a single-use product that delivers fentanyl, an opioid analgesic, in seconds for transmucosal absorption underneath the tongue. Subsys is a transmucosal product to show pain relief when measuring the sum of pain intensity difference at five minutes in a Phase 3 breakthrough cancer pain (BTCP) clinical trial using fentanyl.

Dronabinol Product Family

The Company has an approved dronabinol product and is developing several dronabinol product candidates for the treatment of CINV and appetite stimulation in patients with AIDS, as well as other indications where dronabinol could have potential therapeutic benefits. Dronabinol, the active ingredient in Marinol, is a synthetic cannabinoid whose chemical name is delta-9-tetrahydrocannabinol (THC). Its portfolio consists of its Dronabinol SG Capsule product and Dronabinol RT Capsule product candidate, which are intended to be generic equi! valents to Marinol, in addition to three formulations, including Dronabinol Oral Solution. Dronabinol SG Capsule is a dronabinol soft gelatin capsule intended to be a generic equivalent to Marinol. Dronabinol RT Capsule is a dronabinol soft gel capsule that is stable at room temperature. Dronabinol Oral Solution is a ynthetic THC in an oral liquid formulation.

Cancer Therapeutics

In addition to its cancer-supportive care products, the Company intends to develop cancer therapeutics targeting limitations of existing commercial products. LEP-ETU, it advanced cancer therapeutic, is a NeoLipid liposomal, or microscopic membrane-like structure created from lipids, formulation that incorporates paclitaxel. LEP-ETU completed a Phase 2 clinical trial of 70 patients with metastatic breast cancer.

The Company competes with Cephalon, Inc., BioDelivery Sciences International, Inc., ProStrakan Group plc, Nycomed International Management GmbH, Archimedes Pharma Ltd., TEVA Pharmaceuticals USA, Watson Pharmaceuticals, Inc., AcelRx Pharmaceuticals, Inc., Akela Pharma Inc., Abbott Laboratories, Pharmaceutical International, Inc., Par Pharmaceutical Companies Inc., sanofi-aventis, Eisai Inc., Helsinn Group, Roche Holding AG, Par Pharmaceutical Companies Inc., GlaxoSmithKline plc, ProStrakan Group plc, Merck & Co, GW Pharmaceutical, A.P. Pharma, Inc., Aphios Corp., Roche Holding, Tesaro, Inc., Cornerstone Pharmaceutical, Inc., Bristol-Myers Squibb, Celgene Corporation, Laboratories, Amgen Inc., AstraZeneca PLC., Bayer AG, Biogen Idec Inc., Eisai Co., Ltd., F. Hoffmann- LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Onyx Pharmaceuticals Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Advisors' Opinion:

• [By David Zeiler]

  2. Insys Therapeutics Inc. (Nasdaq: INSY): Insys is a biotech seeking to capitalize on the growing interest in medical marijuana by using a generic form of THC to create drugs to treat cancer pain. INSY had its IPO May 2 with an offer price of $8 a share. The stock rose 19.75% on its first day of trading. But investors really warmed up to Insys later; it currently trades at about $37.54, a 369.25% increase over the offer price.

• [By Roberto Pedone]

  One specialty pharmaceutical player that's quickly moving within range of triggering a big breakout trade is Insys Therapeutics (INSY), which develops and commercialize supportive care products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. This stock is off to a monster start in 2013, with shares up a whopping 434%.

  >>5 Stocks Insiders Love Right Now

  If you take a look at the chart for Insys Therapeutics, you'll notice that this stock has been uptrending strong for the last six months, with shares soaring higher from its low of $9.30 to its recent high of $53.64 a share. During that uptrend, shares of INSY have been making mostly higher lows and higher highs, which is bullish technical price action. Shares of INSY have recently pulled back to its 50-day moving average and the stock has now started to spike higher off that level. That spike is starting to push shares of INSY within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in INSY if it manages to break out above some near-term overhead resistance levels at $43.50 to $44.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 235,266 shares. If that breakout hits soon, then INSY will set up to re-test or possibly take out its next major overhead resistance levels at $47.25 to its all-time high at $53.64 a share.

  Traders can look to buy INSY off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $38.75 a share or near its 50-day at $36.73 a share. One can also buy INSY off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Louis Navellier]

  INSYS Therapeutics (INSY) is a biotech company that focuses on developing pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. Their products include drugs that help patients deal with pain form the disease and help alleviate nausea and pain from chemotherapy. The company reported earnings this week and both profits and sales have exploded higher.

• [By Monica Gerson]

  INSYS Therapeutics (NASDAQ: INSY) is projected to report its Q1 earnings at $0.28 per share on revenue of $45.63 million.

  Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

Top Life Sciences Companies To Invest In Right Now: Provectus Pharmaceuticals Inc (PVCT)

Provectus Pharmaceuticals, Inc., incorporated on May 1, 1978, is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10. The Company has transferred all its intellectual property related to over the counter (OTC) products and non-core technologies to its subsidiaries and designated, such subsidiaries as non-core to its primary business of developing its oncology and dermatology prescription drug candidates. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. The Company is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. All of the Company's prescription drug candidates are in either the pre-clinical or clinical trial stage.

PV-10

As of December 31, 2011, the Company is developing PV-10, a sterile injectible form of rose bengal disodium (Rose Bengal), for direct injection into tumors. Its PV-10 is retained in diseased or damaged tissue but dissipates from healthy tissue. The Company had conducted Phase I and Phase IIstudies of PV-10 for the treatment of metastatic melanoma, and Phase I studies of PV-10 for the treatment of liver and breast cancers.

PH-10

The Company�� prescription drug candidate PH-10 is an aqueous hydrogel formulation of Rose Bengal for topical administration to the skin. The Company is developing PH-10 for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. In August 2011, the Company completed follow-up of all Phase IIc patients.

Over-the-Counter Pharmaceuticals

The Company had desi! gnated its subsidiary that holds its OTC products, GloveAid and Pure-ific, Pure-Stick, Pure N Clear as non-core. The Company�� GloveAid is a hand cream with both antiperspirant and antibacterial properties, for the comfort of users��hands during and after the wearing of disposable gloves. Its Pure-ific line of products includes two quick-drying sprays, Pure-ific and Pure-ific Kids, that immediately kill up to 99.9% of germs on skin and prevent regrowth for six hours. Pure-ific products prevent the spread of germs and thus complement its other OTC products designed to treat irritated skin or skin conditions, such as acne, eczema, dandruff and fungal infections. Its Pure-ific sprays have been designed with convenience in mind and are targeted towards mothers, travelers, and anyone concerned about the spread of sickness-causing germs.

The Company�� acne products Pure-Stick and Pure N Clear work by decreasing the production of fats, oils and sweat that create an environment conducive to unchecked growth of bacteria. Secondly, the products also act to reduce the number bacteria already present. The Pure-Stick and Pure N Clear are applied topically to affected areas there are no safety concerns with healthy skin.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.02 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.

• [By Luke Jacobi]

  Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.38 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.